A Phase 1 Study of LY2787106 in Cancer and Anemia

Phase 1 Completed 33 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelSupportive care

Summary

This study will evaluate the safety LY2787106 in participants with cancer and anemia. It will also evaluate when LY2787106 can improve anemia. This study has two parts: Part A is a dose escalation evaluation. Part B is an evaluation of LY2787106 at a defined dose given with and without iron supplementation.

Timeline

Start: 2010-01
Primary completion: 2014-12
Completion: 2014-12

Publications

Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL Jr, Tiu RV, Wang X, Callies S, Cox J, Tuttle JL, Lau YK, Roeland EJ. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73. doi: 10.1186/s13045-017-0427-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2787106	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	LY2787106	Monoclonal antibody	3 mg/kg	Intravenous
Subject	LY2787106	Monoclonal antibody	10 mg/kg	Intravenous

A Phase 1 Study of LY2787106 in Cancer and Anemia

Summary

Timeline

Publications

Drugs

Indications